Novavax beats, raises 2026 adjusted revenue outlook
Novavax beats Q3 2026 estimates and raises 2026 adjusted revenue outlook to $400M midpoint
- Q3 2026 loss was $0.19 per share, beating consensus for a $0.37 per-share loss.
- Q3 2026 revenue was $68.3M, declined 3% year over year but beat analyst revenue estimates.
- Novavax cut its Q3 2026 net loss to $31M for the reporting period.
- 2026 adjusted revenue outlook increased by $145M, bringing full-year guidance midpoint to $400M.
- Company improved 2026 R&D and SG&A expense guidance for the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.